Hepatic soluble epoxide hydrolase A promising target for unveiling the liver-brain axis in Alzheimer's disease

被引：1
|
作者：
Inoue, Yasuteru [1 ]
Bamkole, Michael [1 ]
Kanekiyo, Takahisa [1 ]
机构：
[1] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA
来源：
NEURON | 2023年 / 111卷 / 18期
关键词：
PATHOLOGY;
D O I：
10.1016/j.neuron.2023.08.019
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Wu and Dong et al.(1) report that hepatic soluble epoxide hydrolase (sEH) manipulation impacts amyloid-beta (A beta) deposits and cognitive impairment in mouse models for Alzheimer's disease (AD), suggesting that hepatic sEH activity is a promising therapeutic target to treat AD.
引用
收藏
页码：2775 / 2777
页数：3
相关论文
共 50 条
  • [21] Genetic evidence for the liver-brain axis: lipid metabolism and neurodegenerative disease risk
    Wang, Zeyu
    Yin, Zixiao
    Sun, Guangyong
    Zhang, Dong
    Zhang, Jianguo
    LIPIDS IN HEALTH AND DISEASE, 2025, 24 (01)
  • [22] The Effects of Alcohol-Induced Hepatic Steroid Hormone Dysregulation on Liver-Brain Axis Function
    Zallar, Lia
    Pleil, Kristen
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 223 - 223
  • [23] Lipocalin 2 Induces Neuroinflammation through Liver-Brain Axis in Nonalcoholic Fatty Liver Disease
    Mondal, Ayan
    Seth, Ratanesh
    Sarkar, Sutapa
    Bose, Dipro
    Saha, Punnag
    Kimono, Diana
    Albadrani, Muayad
    Nagarkatti, Mitzi
    Nagarkatti, Prakash
    Chatterjee, Saurabh
    FASEB JOURNAL, 2020, 34
  • [24] PCSK9 and the Liver-Brain Axis: A Novel Therapeutic Target for Alcohol Use Disorder
    Lee, Jisoo
    Mukhopadhyay, Partha
    Matyas, Csaba
    Trojnar, Eszter
    Paloczi, Janos
    Rosoff, Dan
    Yang, Yuan Ru
    Blank, Brandon
    Savage, Cody
    Vendruscolo, Janaina
    Koob, George
    Vendruscolo, Leandro
    Pacher, Pal
    Lohoff, Falk
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 530 - 530
  • [25] Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics
    Grinan-Ferre, Christian
    Jarne-Ferrer, Julia
    Bellver-Sanchis, Aina
    Codony, Sandra
    Puigoriol-Illamola, Dolors
    Sanfeliu, Coral
    Oh, Yumin
    Lee, Seulki
    Vazquez, Santiago
    Pallas, Merce
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (04)
  • [26] Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer's disease
    Borkowski, Kamil
    Pedersen, Theresa L.
    Seyfried, Nicholas T.
    Lah, James J.
    Levey, Allan, I
    Hales, Chadwick M.
    Dammer, Eric B.
    Blach, Colette
    Louie, Gregory
    Kaddurah-Daouk, Rima
    Newman, John W.
    ALZHEIMERS RESEARCH & THERAPY, 2021, 13 (01)
  • [27] Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease
    Kamil Borkowski
    Theresa L. Pedersen
    Nicholas T. Seyfried
    James J. Lah
    Allan I. Levey
    Chadwick M. Hales
    Eric B. Dammer
    Colette Blach
    Gregory Louie
    Rima Kaddurah-Daouk
    John W. Newman
    Alzheimer's Research & Therapy, 13
  • [28] The bilateral cross communication in microbiota-gut-brain axis as a promising therapeutic target for Alzheimer’s disease: a focus on neuroinflammation
    Awgichew Shewasinad Yehualashet
    Ermiyas Endewunet Melaku
    Demissew Shenkute Gebreyes
    Tilahun Alelign Wassie
    Berhanu Yitayew Sahilu
    Discover Medicine, 2 (1):
  • [29] Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease
    Ren, Qian
    Ma, Min
    Yang, Jun
    Nonaka, Risa
    Yamaguchi, Akihiro
    Ishikawa, Kei-ichi
    Kobayashi, Kenta
    Murayama, Shigeo
    Hwang, Sung Hee
    Saiki, Shinji
    Akamatsu, Wado
    Hattori, Nobutaka
    Hammock, Bruce D.
    Hashimoto, Kenji
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (25) : E5815 - E5823
  • [30] Genetic polymorphisms of microsomal and soluble epoxide hydrolase and the risk of Parkinson's disease
    Farin, FM
    Janssen, P
    Quigley, S
    Abbott, D
    Hassett, C
    Smith-Weller, T
    Franklin, GM
    Swanson, PD
    Longstreth, WT
    Omiecinski, CJ
    Checkoway, H
    PHARMACOGENETICS, 2001, 11 (08): : 703 - 708
12345